Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Non-immunostimulatory nonviral vectors.

Feng Liu1, Lisa M Shollenberger, Leaf Huang

  • 1The center for Pharmacogenetics, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, USA. fliu@pitt.edu or leafh@pitt.edu

FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|September 15, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Success and complication rates of two precut techniques, transpancreatic sphincterotomy and needle-knife sphincterotomy for bile duct cannulation.

Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract·2010
Same author

Effect of Medicaid coverage of tobacco-dependence treatments on smoking cessation.

International journal of environmental research and public health·2010
Same author

Cytokine and autoantibody patterns in acute liver failure.

Journal of immunotoxicology·2009
Same author

A novel scoring system for prognostic prediction in d-galactosamine/lipopolysaccharide-induced fulminant hepatic failure BALB/c mice.

BMC gastroenterology·2009
Same author

Mammalian target of rapamycin signaling pathway contributes to glioma progression and patients' prognosis.

The Journal of surgical research·2009
Same author

Estrogen receptor neurobiology and its potential for translation into broad spectrum therapeutics for CNS disorders.

Current molecular pharmacology·2009

This study developed a novel nonviral gene therapy vector that delivers genes and suppresses inflammation. This dual-function vector shows great potential for safe and effective clinical gene therapy applications.

Area of Science:

  • Biotechnology
  • Gene Therapy
  • Immunology

Background:

  • Viral vectors are efficient but pose safety risks for human gene therapy.
  • Nonviral vectors, particularly lipoplexes, are promising but often induce inflammatory responses.
  • Overcoming inflammation is crucial for the clinical translation of nonviral gene delivery systems.

Purpose of the Study:

  • To develop a nonimmunostimulatory gene delivery vector with dual functions.
  • To enable efficient gene delivery and simultaneous suppression of inflammatory responses.
  • To create a versatile tool for gene therapy and anti-inflammatory drug screening.

Main Methods:

  • Engineered a novel nonviral vector capable of codelivering DNA and anti-inflammatory agents.
  • Tested the vector's ability to deliver various suppressors, including glucocorticoids, NSAIDs, NF-kappaB inhibitors, and natural compounds.

Related Experiment Videos

  • Evaluated the vector's efficacy in suppressing CpG-motif-induced cytokine production (TNF-alpha, IL-12, IFN-gamma) in vivo via intravenous injection.

    • Main Results:

    • Successfully developed a nonimmunostimulatory gene delivery vector.
    • Demonstrated codelivery of genes and multiple types of inflammatory suppressors.
    • Achieved significant suppression of key pro-inflammatory cytokines (TNF-alpha, IL-12, IFN-gamma) after intravenous administration.
    • Showcased the vector's potential for enhancing gene transfer efficiency and in vivo anti-inflammatory drug screening.

    Conclusions:

    • The novel nonviral vector effectively delivers genes while suppressing inflammation, addressing a key limitation of current nonviral systems.
    • This vector holds significant promise for advancing clinical gene therapy applications.
    • The vector offers a unique platform for in vivo screening of anti-inflammatory drugs and enhancing gene transfer efficiency.